Note 4 - Investment in account receivable |
9 Months Ended | ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2020 | |||||||||||||||||||||||||||||||
Notes | |||||||||||||||||||||||||||||||
Note 4 - Investment in account receivable |
Note 4 Investment in account receivable
On April 10, 2015, the Company entered into an exchange agreement whereby the Company received an investment in an account receivable with annual installment payments of $117,000 for 11 years, through 2026, totaling $1,287,000 in exchange for 757,059 shares of Mentor Common Stock obtained through exercise of 757,059 Series D warrants at $1.60 per share plus a $0.10 per warrant redemption price.
The Company valued the transaction based on the market value of Company common shares exchanged in the transaction, resulting in a 17.87% discount from the face value of the account receivable. The discount is being amortized monthly to interest over the 11-year term of the agreement. The investment in account receivable is supported by an exchange agreement and consisted of the following:
For the three months ended September 30, 2020 and 2019, $23,691 and $19,999 of discount amortization is included in interest income, respectively. For the nine months ended September 30, 2020 and 2019, $61,908 and $59,996 of discount amortization is included in interest income, respectively. |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The entire disclosure for financing receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|